tirzepatide fda update Compounding pharmacies can resume making as reconsiders shortage What Is Compounded Tirzepatide? FDA

Patients with prior episodes should avoid tirzepatide unless a clinician decides the benefit clearly outweighs the risk

But symptoms dissipated over time and led to treatment discontinuation in only 4% of patients, they said

Dysesthesia, an unpleasant tingling or burning sensation in the skin, affected about 1 in 5 patients on the 12 mg dose and 1 in 13 on the 9 mg dose though Lilly said most cases were mild and rarely caused participants to drop out

Beckett, 43, said she'd struggled with her weight for years and cycled through diets such as keto and Weight Watchers

It is typically recommended for short-term use only, usually a few weeks to a few months